SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Senomys(SNMX)- A Taste for Success!!!
SNMX 1.4900.0%Nov 5 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
From: lrb3/26/2005 11:54:58 AM
  Read Replies (2) of 192
 
TexasDude,
From your thread header:

One analyst has made the following projections for this Nestle alliance for the savory product:
Nestlé’s global annual sales for the product category that “could” use the (SNMX) savory ingredient are about $6.4 billion. Assuming that only 10% of these sales convert to the (SNMX) enhanced product and that (SNMX) only gets the lowest of the 1-4% royalty range that (SNMX) management has stated that their alliance deals are based, this would generate revenues to (SNMX) of about $64Million dollars. This is a straight revenue source to (SNMX) as the manufacturing cost is to be borne by Nestle. This is only one deal that could bring in $64Million in annual revenue and this isn’t the project that has the most potential for (SNMX) IMO.


I think this analyst has misplaced a decimal point: 10% of $6.4Billion = $640Million, and the 1% royalty on $640Million would be $6.4Million, not $64Million
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext